



Meeting to commence at 10.30 am on Wednesday, 11<sup>th</sup> December 2019  
in the [Cophthorne Hotel Cardiff](#), Culverhouse Cross, Cardiff CF5 6DH

## AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/1219
5. **Chairman's report (verbal update)**
6. **National Prescribing Indicators 2019-20** 2/AWMSG/1219  
- **Analysis of Prescribing Data to June 2019**
7. **Feedback from the AWPAG meeting held 18<sup>th</sup> September 2019** 3/AWMSG/1219
8. **Identifying and delivering the key priorities for AWMSG** 4/AWMSG/1219

*To protect commercial confidentiality the following appraisals will be held in private*

9. **Appraisal 1: Full Submission (WPAS)** 5/AWMSG/1219  
**Glycerol phenylbutyrate (Ravicti<sup>®</sup>)** adjunctive therapy for chronic management of patients with urea cycle disorders including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements) Appendices
10. **Appraisal 2: Full Submission (WPAS)** 6/AWMSG/1219  
**Fampridine (FAMPYRA<sup>®</sup>)** for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4–7) Appendices

*The meeting will open to the public for the announcement of the appraisal recommendations*

11. **Any other business**
12. **Date of next meeting – Tuesday, 11<sup>th</sup> February 2020 in Cardiff**